A boy with X-linked agammaglobulinemia experienced progressive global motor decline, cerebellar syndrome, and epilepsy. All standard polymerase chain reactions for neurotropic viruses were negative on cerebrospinal fluid and brain biopsy. Next-generation sequencing allowed fast identification of a new astrovirus strain (HAstV-VA1/HMO-C-PA), which led to tailor the patient's treatment, with encouraging clinical monitoring over 1 year.
INTRODUCTION
Viral encephalitis is a major cause of morbidity and mortality in patients with inherited primary immunodeficiency (PID) such as X-linked agammaglobulinemia (XLA) [1] . Encephalitis of unknown etiology also constitutes a major challenge, in particular in immunocompromised patients, despite extensive laboratory testing including cultures, reverse transcription-polymerase chain reaction (RT-PCR) and amplicon sequencing [2, 3] . Failure to identify the etiology in infectious encephalitis impairs or delays appropriate therapeutics and increases morbidity and mortality associated with these diseases, notably in patients with PIDs. Infectious encephalitis of unknown etiology probably account for most of undiagnosed progressive cognitive decline in XLA patients. Next-generation sequencing (NGS) is becoming an alternative diagnosis tool for infectious diseases [4] . In this study, we report the case of a boy with unidentified encephalitis in the context of XLA in which NGS led to the identification of a new astrovirus strain related to the VA1/HMO-C group and allowed tailored therapy, with encouraging clinical monitoring over 1 year.
CASE REPORT
A 14-year-old boy with XLA, a genetic disorder affecting B-cell differentiation due to hemizygous mutation in the Bruton tyrosine kinase coding gene, was admitted to the immunology unit with a progressive cognitive decline and recurring seizures over 1 year. He had no peripheral B cell and showed a profound agammaglobulinemia. He was put on substitutive polyvalent intravenous immunoglobulins (IVIG) every 3 weeks and was well until, at 10 years of age, he started to display myoclonic epilepsy with no viral finding (cerebrospinal fluid [CSF], blood, sputum, and stools). A cognitive impairment was noted over the last 4 years (loss of 30 points of Intelligence Quotient [Wechsler Intelligence Scale for Children, WISC-IV]). He was unable to read or write, and his speech was impaired. Clinical examination found ataxia, erratic myoclonies, and dysarthria. In June 2013, brain magnetic resonance imaging (MRI) showed diffuse cortical-subcortical brain atrophy and periventricular hypersignals ( Figure 1A ). Electroencephalography revealed irregular slow-wave activity associated with bilateral frontotemporal spikes but no epileptic discharges. Cerebrospinal fluid analysis was normal for white cell count, for glucose and protein concentrations, and was negative by real-time PCR and RT-PCR for a comprehensive list of neurotropic viruses (Supplementary Table S1 ). Brain biopsy was performed in the right frontal lobe in February 2014. Histologic findings were consistent with acute pan-encephalitis ( Figure 1B) , and all standard PCR and RT-PCR for neurotropic viruses were negative on this biopsy sample (Supplementary  Table S1 ). Total RNAs, as a signature of viral, bacterial, fungal, or protozoan gene expression, were deep sequenced by NGS and analyzed. Large fragments of an astrovirus genome were identified, showing high levels of homology with the VA1/HMO-C clade (a clade distant to those screened by standard RT-PCR). The complete genome was obtained, and this new strain was named HAstV-VA1/HMO-C-PA. It was striking to discover that HAstV-VA1/HMO-C-PA is closely related to 3 astrovirus strains that have been reported recently in human cases of encephalitis, in different immunocompromised contexts including XLA [5] [6] [7] . Specific RT-PCR were designed and were positive on the brain biopsy sample (Supplementary Figure S3) but not on the CSF previously ( June 2013) and concomitantly (March 2014) sampled (for detailed information on methods and results, see Supplementary Data). This virus identification led to an adaptation of treatment and prescription of high-dose IVIG 1 g/kg per day, quickly tapered to 1 g/kg twice and then once a week due to mild clinical intolerance, and 3 bolus of methylprednisolone (1 g/1.73 m 2 for 3 consecutive days). The patient also received intravenous ribavirin for 7 days (30 mg/kg per day, then 15 mg/kg every 6 hours for 4 days, followed by 8 mg/kg every 8 hours for 3 days) and then daily oral ribavirin and 50 μg pegylated interferon (PEG-IFN) alpha-2b per week. He is currently under daily oral ribavirin (800 mg/day, which was later adjusted based on hematologic tolerance) and 50 μg PEG-IFN alpha-2b and 1 g/kg IVIG per week. At month 12 of follow-up, progression in motor behavior and mild memory improvement has been noted. Measured WISC-IV was stable and epilepsy was controlled. Brain atrophy and periventricular hypersignals remained stable upon brain MRI control.
Ethic Statement
Next-generation sequencing analysis was performed on the brain biopsy done for standard diagnostic. Written consent was obtained from the parents for his inclusion in the "Pathodisc" study, which was aimed at identifying pathogens in infectious syndromes of unknown etiology by NGS. Figure 2B ) [8] . Another clade, closer to porcine, mink, and ovine astroviruses, has been identified in a case of human gastroenteritis [9] and is referred to as the VA1/ HMO-C clade. In 2010, a member of this clade was identified as responsible for persistent brain infection leading to dementia and death in a boy with XLA in the United States [5] , and in 2015 2 independent cases coming from the United Kingdom have supported the involvement of VA1/ HMO-C strains in 2 other fatal cases of encephalitis [6, 7] . Thus, we hypothesize that infections by astroviruses belonging to the clade VA1/HMO-C, thought to be highly prevalent in the human population [10] , remain underdiagnosed and might therefore account for a part of nonidentified progressive neurodegeneration in immunocompromised patients. Beyond the VA1/HMO-C group, it should be noted that HAstV4 has been identified, post mortem, in the brain tissue of a 7-month-old boy with severe combined immunodeficiency in the context of disseminated multiorgan infection [11] . More generally, astroviruses have begun to be recognized as causative agents of encephalitis and neurological disorders in cattle [12, 13] and mink [14] , although not belonging to the VA1/HMO-C group, which may suggest different or even species-specific mechanisms of neurotropic infection. Therefore, astroviruses, and in particular members of the VA1/HMO-C clade, complete the list of enteric viruses that, like some enteroviruses (poliovirus vaccine strain, coxsackie viruses, and echoviruses) [15] [16] [17] , may disseminate to the central nervous system despite IVIG reconstitution. Based on other RNA-virus treatment approaches in this setting [18] , treatment was modified upon the diagnosis of astrovirus infection, to include higher doses of IVIG, ribavirin, and PEG-IFN alpha-2b. Mild cognitive improvement was noted after a 12-month follow up, although it is difficult to assess the impact of treatment on the course of the disease. This study illustrates the strength of deep sequencing applied to the diagnosis of infectious diseases, not only in revealing the presence of unpredicted infectious agents in patients' samples but also in identifying genetic virus variants that may not be detected by generic PCRs. This seems particularly relevant for most RNA viruses, whose genomes are highly variable. In the present case, although astroviruses were thought to be a possible etiology, standard PCR was unable to detect the pathogen due its genetic distance from the HAstVs 1-8 clade. Even within the VA1/ HMO-C clade, variations in sequences still exist and may be responsible for the failure of generic PCR amplification (for an illustration, see Supplementary Figure S2 ). Overall, this study is a striking illustration of (1) the limit of targeted, gene-specific approaches applied to the diagnosis of viral diseases and (2) the strength of NGS, for which no a priori on-target sequence is needed.
CONCLUSIONS
Using optimized pipelines and sequencers, results can be delivered within a time short enough for a medical decision shift and clinical benefit [4] . In our case, virus identification was obtained less than 3 days from reception of the sample. Our results extend to viral diseases the demonstration of the usefulness of NGS shown for bacterial diseases, drawn from a case of neuroleptospirosis in a boy with a severe combined immunodeficiency, for which the diagnosis was only established by NGS and led to a rapid and efficient treatment [19] . Because of its increasing availability in the clinics, NGS will probably be applied in a first step to cases where an infectious etiology is likely despite negative extensive search for infectious agents by all available conventional methods.
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